<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>22454182</Do_id>
  <Journal>Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery</Journal>
  <Doc_title>[Resistance and treatment strategy of gastrointestinal stromal tumor target therapy].</Doc_title>
  <Doc_abstract>Gastrointestinal stromal tumor(GIST) originates from interstitial cells of Cajal(ICCs). Tyrosine kinase inhibitors(TKI) such as imatinib and sunitinib, are effective agents besides surgery. However some GIST can become primarily or secondarily resistant to those drugs. The difference in gene mutation types and secondary gene mutation is the main cause. When the GIST is proved to be drug resistance, reasonable personal treatment strategies based on individualized medicine should be made to improve outcomes and quality of life.</Doc_abstract>
  <Doc_ChemicalList>Antineoplastic Agents;Benzamides;Indoles;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Pyrroles;Imatinib Mesylate;sunitinib</Doc_ChemicalList>
  <Doc_meshdescriptors>Antineoplastic Agents;Benzamides;Drug Resistance, Neoplasm;Gastrointestinal Stromal Tumors;Humans;Imatinib Mesylate;Indoles;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Pyrroles</Doc_meshdescriptors>
  <Doc_meshqualifiers>therapeutic use;therapeutic use;genetics;drug therapy;genetics;therapeutic use;therapeutic use;therapeutic use;therapeutic use;therapeutic use</Doc_meshqualifiers>
</Document>
